Monoclonal antibodies in immunodiagnosis and immunotherapy.
Publisher:
Mary Ann Liebert, Inc.
Frequency: Bimonthly
Country: United States
Language: English
Start Year:2013 -
Identifiers
| ISSN: | 2167-9436 (Electronic) 2167-9436 (Linking) |
| NLM ID: | 101590955 |
| (OCoLC): | 794233644 |
| LCCN: | 2012202917 |
Epitope Analysis of an Antihorse Podoplanin Monoclonal Antibody PMab-219. Podoplanin (PDPN), which is a mucin-type membrane glycoprotein, is expressed on lymphatic endothelial cells and epithelial cells of many organs. PDPN is also overexpressed in several malignant cancers, and its expression is associated with cancer progression and poor prognosis. Human PDPN possesses three platelet aggregation-stimulating (PLAG) domains and the PLAG-like domain (PLD), which binds to C-type lectin-like receptor-2 (CLEC-2). Previously, we reported a novel antihorse PDPN (horPDPN) monoclonal antibody (mAb), PMab-219, using Cell-Based Immunization and Screening (CBIS) method. PMab-2...
Anti-Horse Podoplanin Monoclonal Antibody PMab-219 is Useful for Detecting Lymphatic Endothelial Cells by Immunohistochemical Analysis. Podoplanin (PDPN) is expressed in lymphatic endothelial cells, where it induces platelet aggregation through C-type lectin-like receptor-2 (CLEC-2). This protein has been characterized for a number of animal species using specific anti-PDPN monoclonal antibodies (mAbs). We recently established the mAb against horse PDPN (horPDPN) named PMab-219. Therefore, in this study, we investigated whether PMab-219 can detect lymphatic endothelial cells in horse tissues. Immunohistochemical analysis demonstrated that PMab-219 strongly stained lymphatic endothelial cells in horse colon tissues, indicating ...
Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin. Podoplanin (PDPN), a type I transmembrane glycoprotein, is expressed in several body tissues, including podocytes of renal glomerulus, type I alveolar cells of lung, and lymphatic endothelial cells. PDPN activates platelet aggregation by binding to C-type lectin-like receptor-2 (CLEC-2) presented on platelets. Monoclonal antibodies (mAbs) against human-, mouse-, rat-, rabbit-, dog-, bovine-, and cat-PDPN have already been established. However, anti-horse PDPN mAbs have not yet been developed. In this study, we immunized mice with synthetic horse PDPN peptides and developed anti-horse PDPN mAbs...